NCT04156048 (HIV&HEART) is a clinical trial in HIV Infections, sponsored by University Hospital, Essen.

Who is sponsoring NCT04156048?

NCT04156048 is sponsored by University Hospital, Essen.

What condition does NCT04156048 study?

NCT04156048 studies HIV Infections, Coronary Disease, Myocardial Infarction, HIV Encephalopathy, Aging, Heart Failure.

Is NCT04156048 still recruiting?

NCT04156048 is currently completed. Last updated 5 February 2020.

Last reviewed 2020-02-05 · How we verify

NCT04156048: HIV&HEART

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HIV&HEART Aging Study (12,5 Year Follow up)

Completed Last updated 5 February 2020

What this trial tests

trial in HIV Infections in 1,809 participants. Completed in 6 November 2019.

Timeline

3 July 2017

Primary endpoint
31 October 2019

6 November 2019

Quick facts

Lead sponsor	University Hospital, Essen
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,809
Start date	3 July 2017
Primary completion	31 October 2019
Estimated completion	6 November 2019
Sites	6 locations across Germany

Conditions studied

HIV Infections — all drugs for HIV Infections →
Coronary Disease — all drugs for Coronary Disease →
Myocardial Infarction — all drugs for Myocardial Infarction →
HIV Encephalopathy — all drugs for HIV Encephalopathy →

Sponsor

University Hospital, Essen

Who can join

18 and older, any sex, with HIV Infections or Coronary Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The HIV/HEART Aging study (HIVH) is an ongoing, prospective, multicentre trial that was conducted to assess the incidence, the prevalence and the clinical course of cardiovascular diseases (CVD) in HIV-infected patients. The study population includes outpatients from specialized HIV-care units of the German Ruhr region, who were at least 18 years of age, were known to have a HIV-infection and exhibited a stable disease status within 4 weeks before inclusion into the trial. From March 2004 (Pilot phase) to October 2019 (12,5 year Follow-up) 1806 HIV+ patients were recruited in a consecutive manner. The standardised examinations included a targeted assessment of medical history and physical examination. Blood was drawn for comprehensive laboratory tests including HIV specific parameters (CD4 cell count, HIV-1 RNA levels) and cardiovascular items (lipid concentrations, BNP values and renal parameters). Furthermore, non-invasive tests were performed during the initial visit, including additional heart rate and blood pressure measurements, electrocardiogram (ECGs) and transthoracic echocardiography (TTE). Examinations were completed in accordance with previously defined standard operating procedures. CVD were defined as coronary, cerebrovascular, peripheral arterial disease, heart failure or cardiac vitium.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Current insights into transcriptional role(s) for the nutraceutical <i>Withania somnifera</i> in inflammation and aging.
Saha P, Ajgaonkar S, Maniar D, Sahare S, et al · · 2024 · cited 13× · PMID 38765810 · DOI 10.3389/fnut.2024.1370951

Verify or expand the search:

Other recruiting trials for HIV Infections

Currently open trials in the same condition.

NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting

Other University Hospital, Essen trials

Trials by the same sponsor.

NCT07409584 — Mental Health and Suicidality in Glioblastoma Patients in Germany · recruiting
NCT07359690 — Multimodal Analysis of Endomyocardial Biopsies · recruiting
NCT06388369 — Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer · Phase 1, PHASE2 · terminated
NCT07130526 — Distrupt Stiffness Trial · NA · recruiting
NCT07343466 — Quality of Life and the Influence of Stress on the Postoperative Course of Patients After Device Implantation · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04156048 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Essen
Last refreshed: 5 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04156048.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing